Basilea’s antifungal isavuconazole passed phase III clinical trial futility analysis
By Frontier India Pharmacetuicals News | January 29th, 2010 | Category: Medical Company News, New Medicine News | No Comments »Basilea Pharmaceutica Ltd. announced that based on a futility analysis of the isavuconazole phase III trial for the treatment of invasive Aspergillus infections, the Independent Data Safety Monitoring Board (IDSMB) has recommended the continuation of the study.
The primary goal of this phase III study is to demonstrate statistical non-inferiority of isavuconazole versus the comparator, current [...]